Combining PYX-201 with Pembrolizumab for Advanced Solid Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to determine the recommended Phase 2 doses and maximum tolerated dose of PYX-201 when used in combination with pembrolizumab for patients with advanced solid tumors. Participants will include those with various types of advanced cancers, such as head and neck squamous cell carcinoma and triple-negative breast cancer. The study will assess the safety and efficacy of this combination therapy through a series of evaluations and measurements. Fresh tumor biopsies or archived tumor tissue samples will be required for participant eligibility.

Why it matters

Who can join: the full rules

Inclusion Criteria

1. Histologically or cytologically confirmed advanced solid tumors, including first-line (1L) head and neck squamous cell carcinoma (HNSCC), advanced or metastatic triple negative breast cancer (TNBC), hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative breast cancer (HER2- BC), gastric cancer (GC), cervical cancer, and second-line and higher (2L+) HNSCC.
2. Male or non-pregnant, non-lactating female participants age ≥18 years.
3. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 to 1.
4. Participant must have at least 1 measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.
5. Life expectancy of \>3 months, in the opinion of the Investigator.
6. Adequate hematologic function.
7. Adequate hepatic function.
8. Adequate renal function.
9. Adequate coagulation profile.
10. Clinical sites must conduct fresh tumor biopsy or provide participant's archived tumor tissue sample.

Exclusion Criteria

1. Known additional malignancy that is progressing or has required active treatment within the past 2 years.
2. Have any active central nervous system (CNS) metastases and/or carcinomatous meningitis.
3. Significant cardiovascular disease within 6 months prior to start of study drug.
4. Evidence of an active systemic bacterial, fungal, or viral infection requiring treatment at the start of study drug.
5. Known active hepatitis B virus (HBV), hepatitis C virus (HCV), human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS).
6. Failure to recover to Baseline severity or National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 Grade ≤1 from acute non-hematologic toxicity due to previous therapy, prior to Screening.
7. Participants with Grade \>1 neuropathy of any grade per CTCAE v5.0 and/or receiving treatment for neuropathy at Screening.
8. History of uncontrolled diabetes mellitus.
9. Participants with immunodeficiency or active autoimmune disease that is contraindicated for pembrolizumab.
10. Participants with a history of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/ILD.
11. Prior solid organ or bone marrow progenitor cell transplantation.
12. Prior high-dose chemotherapy requiring stem cell rescue.
13. Previously received treatment with a programmed death-1 (PD-1)/L1 inhibitor any prior treatment with an agent directed to another stimulatory or co inhibitory T-cell receptor.
14. Severe hypersensitivity (Grade ≥3) to pembrolizumab and/or any of its excipients and/or PYX-201 and/or any of its excipients.

Where it's running

• University of California San Diego
  San Diego, California, United States Recruiting
• Sarcoma Oncology Center
  Santa Monica, California, United States Recruiting
• Moffitt Cancer Center
  Tampa, Florida, United States Recruiting
• University of Chicago
  Chicago, Illinois, United States Recruiting
• Massachusetts General Hospital
  Boston, Massachusetts, United States Recruiting
• Dana-Farber Cancer Institute
  Boston, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: Pyxis Oncology Clinical Trial Team
• Email: clinicaltrials@pyxisoncology.com
• Phone: 617-453-3596

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• EIK1005 (Werner helicase inhibitor) alone or with pembrolizumab for advanced MSI-H/dMMR and other solid tumors

  This trial tests whether EIK1005, given alone or together with pembrolizumab, can be safely given and help people with advanced solid tumors, especially MSI‑H/dMMR cancers.

  Recruiting at 44 sites Phase 1/2 Eikon Therapeutics · Los Angeles, California and 44 other locations · NCT07262619

• ABX-001 alone or with pembrolizumab for advanced solid tumors

  This tests whether the new immunotherapy ABX-001, given alone or with pembrolizumab, is safe and shows signs of benefit in adults with advanced solid tumors that have stopped responding to prior treatments.

  Recruiting at 5 sites Phase 1 Abalos Therapeutics GmbH · Berlin and 4 other locations · NCT07231458

• CKD-512 alone and with pembrolizumab for advanced or metastatic solid tumors

  This study will try CKD-512 by itself and together with pembrolizumab in people with advanced or metastatic solid tumors who have exhausted standard treatments.

  Recruiting Phase 1 Chong Kun Dang Pharmaceutical · Seoul · NCT07215637

• Testing M3T01 alone and with pembrolizumab or standard chemotherapies for advanced solid tumors

  This trial tests whether the antibody M3T01, by itself or with pembrolizumab or standard chemotherapies, is safe and might help adults with metastatic or unresectable solid tumors.

  Recruiting Phase 1 Providence Health & Services · Portland, Oregon · NCT06719362

• Evaluating TEV-56278 alone or with Pembrolizumab for advanced solid tumors

  This study is testing a new treatment called TEV-56278, both alone and with another drug called Pembrolizumab, to see if it helps people with advanced solid tumors.

  Recruiting at 11 sites Phase 1 Teva Branded Pharmaceutical Products R&D, Inc. · Los Angeles, California and 11 other locations · NCT06480552

• Lenvatinib and Pembrolizumab With or Without SBRT for Metastatic Kidney Cancer

  This study tests whether adding SBRT to standard lenvatinib plus pembrolizumab helps people with metastatic kidney cancer who have stable disease after initial treatment.

  Recruiting at 8 sites Phase 2 Kidney Cancer Research Bureau · Kazan' and 7 other locations · NCT07928167

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.